{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:13:30Z","timestamp":1762866810856},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T00:00:00Z","timestamp":1455494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T00:00:00Z","timestamp":1455494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/bmt.2016.15","type":"journal-article","created":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T14:40:43Z","timestamp":1455547243000},"page":"869-871","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy"],"prefix":"10.1038","volume":"51","author":[{"given":"N","family":"Kawashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Kagaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Watakabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kurahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"BFbmt201615_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/sj.bmt.1705038","volume":"36","author":"KW Song","year":"2005","unstructured":"Song KW, Lipton J . Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplant 2005; 36: 183\u2013191.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201615_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/bmt.2013.186","volume":"49","author":"P Chevallier","year":"2014","unstructured":"Chevallier P, Labopin M, Milpied N, Bilger K, Socie G, Yakoub-Agha I et al. Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2014; 49: 361\u2013365.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201615_CR3","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1182\/blood-2013-07-514448","volume":"122","author":"EA Copelan","year":"2013","unstructured":"Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood 2013; 122: 3863\u20133870.","journal-title":"Blood"},{"key":"BFbmt201615_CR4","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","volume":"122","author":"C Bredeson","year":"2013","unstructured":"Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 2013; 122: 3871\u20133878.","journal-title":"Blood"},{"key":"BFbmt201615_CR5","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/bmt.2010.253","volume":"46","author":"J Inagaki","year":"2011","unstructured":"Inagaki J, Nagatoshi Y, Sakiyama M, Nomura Y, Teranishi H, Sasaki T et al. TBI and melphalan followed by allogeneic hematopoietic SCT in children with advanced hematological malignancies. Bone Marrow Transplant 2011; 46: 1057\u20131062.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201615_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1046\/j.1365-2141.1999.01424.x","volume":"105","author":"M Murata","year":"1999","unstructured":"Murata M, Nishida T, Haneda M, Kanie T, Taji H, Iida H et al. A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. Br J Haematol 1999; 105: 799\u2013802.","journal-title":"Br J Haematol"},{"key":"BFbmt201615_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/sj.bmt.1701244","volume":"21","author":"N Hirabayashi","year":"1998","unstructured":"Hirabayashi N, Goto S, Ishii M, Yuge M, Mitsuma A, Noda N . Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia. Bone Marrow Transplant 1998; 21: 1079\u20131083.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201615_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/bmt.2012.236","volume":"48","author":"R Martino","year":"2013","unstructured":"Martino R, de Wreede L, Fiocco M, van Biezen A, von dem Borne PA, Hamladji RM et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow Transplant 2013; 48: 761\u2013770.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201615_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1200\/JCO.1996.14.1.220","volume":"14","author":"JE Anderson","year":"1996","unstructured":"Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220\u2013226.","journal-title":"J Clin Oncol"},{"key":"BFbmt201615_CR10","first-page":"21","volume":"3","author":"G Helenglass","year":"1988","unstructured":"Helenglass G, Powles RL, McElwain TJ, Lakhani A, Milan S, Gore M et al. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission. Bone Marrow Transplant 1988; 3: 21\u201329.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201615_CR11","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 3730\u20133738.","journal-title":"J Clin Oncol"},{"key":"BFbmt201615_CR12","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1182\/blood-2008-03-145862","volume":"113","author":"Y Kuwatsuka","year":"2009","unstructured":"Kuwatsuka Y, Miyamura K, Suzuki R, Kasai M, Maruta A, Ogawa H et al. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. Blood 2009; 113: 2096\u20132103.","journal-title":"Blood"},{"key":"BFbmt201615_CR13","first-page":"513","volume":"91","author":"A Gratwohl","year":"2006","unstructured":"Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513\u2013521.","journal-title":"Haematologica"},{"key":"BFbmt201615_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2013.52.6582","volume":"32","author":"EJ Chow","year":"2014","unstructured":"Chow EJ, Baker KS, Lee SJ, Flowers ME, Cushing-Haugen KL, Inamoto Y et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol 2014; 32: 191\u2013198.","journal-title":"J Clin Oncol"},{"key":"BFbmt201615_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1681\/ASN.2006020118","volume":"17","author":"S Hingorani","year":"2006","unstructured":"Hingorani S . Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol 2006; 17: 1995\u20132005.","journal-title":"J Am Soc Nephrol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201615.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201615","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201615.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:13:56Z","timestamp":1648062836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,15]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFbmt201615"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.15","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,15]]},"assertion":[{"value":"15 February 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}